Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of ...
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO ...
来自MSN24 天
Novel mRNA-based therapy offers hope for patients with proliferative vitreoretinopathy Mass ...
A new preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR ...